UHN COVID-19 Biobank , Canada

Registration Status: Completed

Objective: The UHN COVID-19 Biobank is an investigator-initiated biobanking program that collects and archives biological specimens and data obtained from confirmed and/or suspected COVID-19 positive patients and stores them for future research purposes. The UHN COVID-19 was founded in 2020 to test the primary hypothesis of measuring severity markers (i.e. circulating markers of endothelial and immune activation) at clinical presentation are early prognostic indicators of COVID-19. With hopes of expediting and facilitating research amidst the COVID-19 pandemic, the UHN COVID-19 Biobank is a valuable resource that will serve as a library for researchers, facilitating access to high quality biospecimens collected longitudinally throughout the course of the infection. Our biospecimens will be housed indefinitely, as they are essential in understanding key aspects of the disease, including, how to detect infection, how to prevent infection and the development of a COVID-19 vaccine and/or potential treatments. Our highly trained personnel at UHN Biospecimen Services can provide expertise and services in: recruitment, consenting, procurement, processing, storage and shipment of biofluids.

Registered Biobank Name UHN COVID-19 Biobank
Biobank Leader Heidi Wagner
Country Canada
Email for biobank inquiries Heidi.Wagner@uhn.ca
Principal Investigator Dr. Neil Fleshner (Principal Investigator) and Heidi Wagner (Head of Operations)
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: